These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33904111)

  • 21. Understanding risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S
    Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?
    Brooks MJ
    Mayo Clin Proc; 2014 Dec; 89(12):1673-84. PubMed ID: 25441401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk evaluation mitigation strategies: the evolution of risk management policy.
    Hollingsworth K; Toscani M
    Popul Health Manag; 2013 Apr; 16(2):132-7. PubMed ID: 23113627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A safe in-home disposal system with every opioid prescription? Food and Drug Administration is considering a potential new Risk Evaluation and Mitigation Strategy that could impact pharmacists.
    Stubbings J; Crawford SY; Menighan TE
    J Am Pharm Assoc (2003); 2022; 62(2):413-418. PubMed ID: 34872856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S; Tichy EM
    Prog Transplant; 2013 Mar; 23(1):58-62; quiz 63. PubMed ID: 23448822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system.
    American Pharmacists Association
    J Am Pharm Assoc (2003); 2009; 49(6):729-43. PubMed ID: 19926553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the impact of mifepristone's risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics✰,✰✰.
    Razon N; Wulf S; Perez C; McNeil S; Maldonado L; Fields AB; Carvajal D; Logan R; Dehlendorf C
    Contraception; 2022 May; 109():19-24. PubMed ID: 35131289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the approved Risk Evaluation and Mitigation Strategy programs for New Drug Applications and Biologics Licensing Applications.
    Johnson NA; Priefer R
    Regul Toxicol Pharmacol; 2019 Feb; 101():53-56. PubMed ID: 30473489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function.
    Blanchette CM; Nunes AP; Lin ND; Mortimer KM; Noone J; Tangirala K; Johnston S; Gutierrez B
    Drugs Context; 2015; 4():. PubMed ID: 25709706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?
    Wilson A; Milne CP
    Food Drug Law J; 2011; 66(4):569-85, ii. PubMed ID: 24505829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
    Nicholson S; Peterson J; Yektashenas B
    Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of risk evaluation and mitigation strategies in oncology: summary of the oncology risk evaluation and mitigation strategies workshop.
    Frame JN; Jacobson JO; Vogel WH; Griffith N; Wariabharaj D; Garg R; Zon R; Stephens CL; Bialecki AM; Bruinooge SS; Allen SL
    J Oncol Pract; 2013 Mar; 9(2):e24-39. PubMed ID: 23814522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
    Slevin KA; Ashburn MA
    J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.
    Childs L; Alexander E; Duong MT
    Am J Health Syst Pharm; 2012 May; 69(10):885-9. PubMed ID: 22555085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
    Peppin JF; Coleman JJ; Kirsh KL
    Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anatomy of Risk Evaluation and Mitigation Strategies (REMS).
    Loeser KK; McKoy JM; Schumock GT
    Cancer Treat Res; 2019; 171():93-105. PubMed ID: 30552659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Adds Online REMS Table.
    Aschenbrenner DS
    Am J Nurs; 2017 Nov; 117(11):21. PubMed ID: 29076851
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk Evaluation and Mitigation Strategies With Elements to Assure Safe Use: Alignment of the Goals With the Tools to Manage Risk.
    Cronin M; Berger S; Seligman PJ
    Ther Innov Regul Sci; 2014 Nov; 48(6):724-733. PubMed ID: 30227470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
    Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
    Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.